[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Genmab A/S ADR CARL JACOBSENS VEJ 30 VALBY G7 2500 DNK

www.genmab.com Employees: 3,029 P: 45-7020-2728 F: +45 70202729

Sector:

Medical

Description:

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.

Key Statistics

Overview:

Market Capitalization, $K 16,441,880
Enterprise Value, $K 20,000,880
Shares Outstanding, K 623,507
Float, K 613,905
% Float 98.46%
Short Interest, K 8,497
Short Float 1.36%
Days to Cover 5.17
Short Volume Ratio 0.43
% of Insider Shareholders 1.54%
% of Institutional Shareholders 7.07%

Financials:

Annual Sales, $ 3,720 M
Annual Net Income, $ 963,000 K
Last Quarter Sales, $ 896,000 K
Last Quarter Net Income, $ 53,000 K
EBIT, $ 1,242 M
EBITDA, $ 1,313 M

Growth:

1-Year Return 27.25%
3-Year Return -36.78%
5-Year Return -36.78%
5-Year Revenue Growth 140.15%
5-Year Earnings Growth 37.50%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.15 on 05/07/26
Next Earnings Date 08/06/26
Earnings Per Share ttm 1.39
EPS Growth vs. Prev Qtr 200.00%
EPS Growth vs. Prev Year -51.61%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 5-1 on 05/01/18

GMAB Ratios

Ratio
Price/Earnings ttm 19.09
Price/Earnings forward 22.30
Price/Earnings to Growth 1.54
Return-on-Equity % 15.34%
Return-on-Assets % 8.94%
Profit Margin % 25.89%
Debt/Equity 0.92
Price/Sales 4.45
Price/Cash Flow 16.49
Price/Book 2.91
Book Value/Share 9.11
Interest Coverage 5.48
60-Month Beta 0.86
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.